Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two […]
Autor: Firma Kuros Biosciences
Kuros Biosciences announces MagnetOs sales and distribution agreements across Northern Europe
Agreements in Netherlands, Switzerland and Austria and letter of intent in Finland Supports further acceleration of sales of MagnetOs bone graft Kuros Biosciences (SIX: KURN) today announced that it has […]
Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week
. Industry-leading award recognizes Kuros’ Fibrin-PTH (KUR-113) technology Rounds off successful year of commercial, clinical, and financial progress Kuros also wins GHP Magazine’s 2020 International Life Science Award Kuros Biosciences […]
Kuros announces results of Rights Offering
Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of its Rights Offering, first announced on October 5, 2020, in which a total of up to 8,426,229 newly […]
Kuros Biosciences to present new data on the role of osteoimmunology in bone formation at NASS 2020 Annual Meeting
Kuros Biosciences today announced it will unveil new research on the role of osteoimmunology in bone formation in three presentations at the North American Spine Society (NASS) 2020 Annual Meeting, […]
Kuros Biosciences reports MagnetOs products approved in Australia
MagnetOs Granules and MagnetOs Putty receive TGA approval in Australia Initial launch of MagnetOs on the Australian market scheduled for late Q1 2021. Kuros Biosciences BV, the Dutch subsidiary of […]
Kuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, will host an expert perspectives webinar on pioneering solutions for targeted and controlled bone healing on Wednesday, October […]
Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft
Strong adoption by spinal surgeons since U.S. launch in September 2019 Sales accelerating with over 2,000 patients treated to date Kuros Biosciences (SIX: KURN) today announced that over 2,000 patients […]
Kuros Convenes Extraordinary General Meeting
Kuros Biosciences (SIX: KURN) today announced that it will hold an Extraordinary General Meeting (EGM) of shareholders to seek approval to increase the Company’s ordinary share capital. The EGM will […]
Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH
First investigational trial of a drug-biologic bone graft for spine fusion Phase 2 trial in the U.S. compares Fibrin-PTH (KUR-113) with local autograft Primary endpoint is radiographic interbody fusion at […]